<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">39361171</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>03</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1432-1912</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2024</Year><Month>Oct</Month><Day>03</Day></PubDate></JournalIssue><Title>Naunyn-Schmiedeberg's archives of pharmacology</Title><ISOAbbreviation>Naunyn Schmiedebergs Arch Pharmacol</ISOAbbreviation></Journal><ArticleTitle>An updated landscape on nanopharmaceutical delivery for mitigation of colon cancer.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00210-024-03482-0</ELocationID><Abstract><AbstractText>Globally, colorectal cancer (CRC) continues to rank among the leading causes of cancer-related death. Systemic toxicity, multidrug resistance, and nonspecific targeting often pose challenges to conventional therapy for CRC. Because it is a complex disease with a complex genetic and environmental pathophysiology, advanced therapeutic strategies are needed. Nanotechnology presents a potential solution that may maximize therapeutic efficacy while minimizing negative effects by enabling personalized delivery of anticancer drugs. This review focuses on recent developments in colorectal drug delivery systems based on nanotechnology. Numerous nanomaterials, including liposomes, dendrimers, micelles, exosomes, and gold nanoparticles, are developed and used. Distinctive characteristics of mentioned nanocarriers are discussed along with strategies that can be employed for enhancing the delivery of drugs to colorectal cancer cells. The review also quotes the most relevant preclinical and clinical studies that show how these nanomaterials improve drug solubility, stability, and targeted delivery while overcoming the shortcomings of conventional therapies. Nanotechnology has made CRC treatment very efficient and advanced, which has opened up new possibilities for targeted drug delivery. Preclinical and clinical studies have also proved that the use of nano-formulations in colon-specific delivery systems have significant results, indicating potential for better patient outcomes. Future research can be done in order to overcome the hurdles regarding biocompatibility, expansion, and regulatory challenges. Large-scale clinical trials and nanomaterial formulation optimization should be the main goals of future research to confirm the efficacy and safety of these novel treatments.</AbstractText><CopyrightInformation>© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Shahzad</LastName><ForeName>Maria</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Faculty of Pharmaceutical Sciences, University of Central Punjab (UCP), Lahore, 54000, Pakistan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hameed</LastName><ForeName>Huma</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0002-8636-8644</Identifier><AffiliationInfo><Affiliation>Faculty of Pharmaceutical Sciences, University of Central Punjab (UCP), Lahore, 54000, Pakistan. huma.hameed@ucp.edu.pk.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Amjad</LastName><ForeName>Ayesha</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Faculty of Food Technology and Nutrition Sciences, Lahore University of Biological and Applied Sciences, Lahore, 54000, Pakistan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Khan</LastName><ForeName>Mahtab Ahmad</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Faculty of Pharmaceutical Sciences, University of Central Punjab (UCP), Lahore, 54000, Pakistan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Qureshi</LastName><ForeName>Inaba Shujaat</ForeName><Initials>IS</Initials><AffiliationInfo><Affiliation>Department of Human Nutrition and Dietetics, Faculty of Rehabilitation and Allied Health Sciences, Riphah International University, Gulberg III, Lahore, 54000, Pakistan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hameed</LastName><ForeName>Anam</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Human Nutrition and Dietetics, Faculty of Rehabilitation and Allied Health Sciences, Riphah International University, Gulberg III, Lahore, 54000, Pakistan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saeed</LastName><ForeName>Asad</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Faculty of Pharmaceutical Sciences, University of Central Punjab (UCP), Lahore, 54000, Pakistan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Munir</LastName><ForeName>Rabia</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Pharmaceutics, Faculty of Pharmaceutical Sciences, Government College University Faisalabad, Faisalabad, 38000, Pakistan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Naunyn Schmiedebergs Arch Pharmacol</MedlineTA><NlmUniqueID>0326264</NlmUniqueID><ISSNLinking>0028-1298</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Cancer</Keyword><Keyword MajorTopicYN="N">Colon cancer</Keyword><Keyword MajorTopicYN="N">Colorectal cancer</Keyword><Keyword MajorTopicYN="N">Nanoparticles</Keyword><Keyword MajorTopicYN="N">Nanotechnology</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>8</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>3</Day><Hour>12</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>3</Day><Hour>12</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>3</Day><Hour>11</Hour><Minute>15</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39361171</ArticleId><ArticleId IdType="doi">10.1007/s00210-024-03482-0</ArticleId><ArticleId IdType="pii">10.1007/s00210-024-03482-0</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Abedizadeh R, Majidi F, Khorasani HR et al (2024) Colorectal cancer: a comprehensive review of carcinogenesis, diagnosis, and novel strategies for classified treatments. Cancer Metastasis Rev 43:729–753. https://doi.org/10.1007/s10555-023-10158-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10555-023-10158-3</ArticleId><ArticleId IdType="pubmed">38112903</ArticleId></ArticleIdList></Reference><Reference><Citation>Adebayo AS, Agbaje K, Adesina SK, Olajubutu O (2023) Colorectal cancer: disease process, current treatment options, and future perspectives. Pharmaceutics 15:2620. https://doi.org/10.3390/pharmaceutics15112620</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/pharmaceutics15112620</ArticleId><ArticleId IdType="pubmed">38004598</ArticleId><ArticleId IdType="pmc">10674471</ArticleId></ArticleIdList></Reference><Reference><Citation>Advani SM, Swartz MD, Loree J et al (2021) Epidemiology and molecular-pathologic characteristics of CpG island methylator phenotype (CIMP) in colorectal cancer. Clin Colorectal Cancer 20:137-147.e1. https://doi.org/10.1016/j.clcc.2020.09.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clcc.2020.09.007</ArticleId><ArticleId IdType="pubmed">33229221</ArticleId></ArticleIdList></Reference><Reference><Citation>Aggarwal A, Han L, Boyle J et al (2023) Association of quality and technology with patient mobility for colorectal cancer surgery. JAMA Surg 158:e225461. https://doi.org/10.1001/jamasurg.2022.5461</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamasurg.2022.5461</ArticleId><ArticleId IdType="pubmed">36350616</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmad R, Singh JK, Wunnava A et al (2021) Emerging trends in colorectal cancer: dysregulated signaling pathways (Review). Int J Mol Med 47:1–1. https://doi.org/10.3892/ijmm.2021.4847</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/ijmm.2021.4847</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmadi M, Jafari R, Mahmoodi M, Rezaie J (2021) The tumorigenic and therapeutic functions of exosomes in colorectal cancer: opportunity and challenges. Cell Biochem Funct 39:468–477. https://doi.org/10.1002/cbf.3622</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cbf.3622</ArticleId><ArticleId IdType="pubmed">33491214</ArticleId></ArticleIdList></Reference><Reference><Citation>Ajeeshkumar KK, Aneesh PA, Raju N et al (2021) Advancements in liposome technology: preparation techniques and applications in food, functional foods, and bioactive delivery: a review. Compr Rev Food Sci Food Saf 20:1280–1306. https://doi.org/10.1111/1541-4337.12725</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/1541-4337.12725</ArticleId><ArticleId IdType="pubmed">33665991</ArticleId></ArticleIdList></Reference><Reference><Citation>Akbari M, Shomali N, Faraji A et al (2020) CD133: an emerging prognostic factor and therapeutic target in colorectal cancer. Cell Biol Int 44:368–380. https://doi.org/10.1002/cbin.11243</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cbin.11243</ArticleId><ArticleId IdType="pubmed">31579983</ArticleId></ArticleIdList></Reference><Reference><Citation>Albadari N, Xie Y, Li W (2024) Deciphering treatment resistance in metastatic colorectal cancer: roles of drug transports, EGFR mutations, and HGF/c-MET signaling. Front Pharmacol 14. https://doi.org/10.3389/fphar.2023.1340401</Citation></Reference><Reference><Citation>Ali SR, Deori C, Gogoi GK et al (2024) Liposomic nano particles in the treatment of colorectal and ovarian cancer. Eur J Med Chem Rep 11:100149. https://doi.org/10.1016/j.ejmcr.2024.100149</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejmcr.2024.100149</ArticleId></ArticleIdList></Reference><Reference><Citation>Alibolandi M, Hoseini F, Mohammadi M et al (2018) Curcumin-entrapped MUC-1 aptamer targeted dendrimer-gold hybrid nanostructure as a theranostic system for colon adenocarcinoma. Int J Pharm 549:67–75. https://doi.org/10.1016/j.ijpharm.2018.07.052</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijpharm.2018.07.052</ArticleId><ArticleId IdType="pubmed">30048777</ArticleId></ArticleIdList></Reference><Reference><Citation>Alomrani A, Badran M, Harisa GI et al (2019) The use of chitosan-coated flexible liposomes as a re rkable carrier to enhance the antitumor efficacy of 5-fluorouracil against colorectal cancer. Saudi Pharm J 27:603–611. https://doi.org/10.1016/j.jsps.2019.02.008</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jsps.2019.02.008</ArticleId><ArticleId IdType="pubmed">31297013</ArticleId></ArticleIdList></Reference><Reference><Citation>Alzahrani SM, Al Doghaither HA, Al-Ghafari AB (2021) General insight into cancer: an overview of colorectal cancer (Review). Mol Clin Oncol 15:1–8. https://doi.org/10.3892/mco.2021.2433</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/mco.2021.2433</ArticleId></ArticleIdList></Reference><Reference><Citation>Aqeel R, Srivastava N, Kushwaha P (2022) Micelles in cancer therapy: an update on preclinical and clinical status. Recent Pat Nanotechnol 16:283–294. https://doi.org/10.2174/1872210515666210720125717</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1872210515666210720125717</ArticleId><ArticleId IdType="pubmed">34303336</ArticleId></ArticleIdList></Reference><Reference><Citation>Ashique S, Bhowmick M, Pal R et al (2024) Multi drug resistance in colorectal cancer- approaches to overcome, advancements and future success. Adv Cancer Biol - Metastasis 10:100114. https://doi.org/10.1016/j.adcanc.2024.100114</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.adcanc.2024.100114</ArticleId></ArticleIdList></Reference><Reference><Citation>Ashrafizadeh M, Zarrabi A, Hashemi F et al (2020) Polychemotherapy with curcumin and doxorubicin via biological nanoplatforms: enhancing antitumor activity. Pharmaceutics 12:1084. https://doi.org/10.3390/pharmaceutics12111084</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/pharmaceutics12111084</ArticleId><ArticleId IdType="pubmed">33187385</ArticleId></ArticleIdList></Reference><Reference><Citation>Baidoun F, Elshiwy K, Elkeraie Y et al (2021) Colorectal cancer epidemiology: recent trends and impact on outcomes. Curr Drug Targets 22:998–1009. https://doi.org/10.2174/1389450121999201117115717</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1389450121999201117115717</ArticleId><ArticleId IdType="pubmed">33208072</ArticleId></ArticleIdList></Reference><Reference><Citation>Bender U, Rho YS, Barrera I et al (2019) Adjuvant therapy for stages II and III colon cancer: risk stratification, treatment duration, and future directions. Curr Oncol Tor Ont 26:S43–S52. https://doi.org/10.3747/co.26.5605</Citation><ArticleIdList><ArticleId IdType="doi">10.3747/co.26.5605</ArticleId></ArticleIdList></Reference><Reference><Citation>Biller LH, Schrag D (2021) Diagnosis and treatment of metastatic colorectal cancer: a review. JAMA 325:669–685. https://doi.org/10.1001/jama.2021.0106</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2021.0106</ArticleId><ArticleId IdType="pubmed">33591350</ArticleId></ArticleIdList></Reference><Reference><Citation>Bober Z, Bartusik-Aebisher D, Aebisher D (2022) Application of dendrimers in anticancer diagnostics and therapy. Molecules 27:3237. https://doi.org/10.3390/molecules27103237</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/molecules27103237</ArticleId><ArticleId IdType="pubmed">35630713</ArticleId></ArticleIdList></Reference><Reference><Citation>Brar B, Ranjan K, Palria A et al (2021) Nanotechnology in colorectal cancer for precision diagnosis and therapy. Front Nanotechnol 3. https://doi.org/10.3389/fnano.2021.699266</Citation></Reference><Reference><Citation>Cabeza L, Perazzoli G, Mesas C et al (2020) Nanoparticles in colorectal cancer therapy: latest in vivo assays, clinical trials, and patents. AAPS PharmSciTech 21:178. https://doi.org/10.1208/s12249-020-01731-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1208/s12249-020-01731-y</ArticleId><ArticleId IdType="pubmed">32591920</ArticleId></ArticleIdList></Reference><Reference><Citation>Cardoso R, Guo F, Heisser T et al (2021) Colorectal cancer incidence, mortality, and stage distribution in European countries in the colorectal cancer screening era: an international population-based study. Lancet Oncol 22:1002–1013. https://doi.org/10.1016/S1470-2045(21)00199-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1470-2045(21)00199-6</ArticleId><ArticleId IdType="pubmed">34048685</ArticleId></ArticleIdList></Reference><Reference><Citation>Carlsen L, Huntington KE, El-Deiry WS (2022) Immunotherapy for colorectal cancer: mechanisms and predictive biomarkers. Cancers 14:1028. https://doi.org/10.3390/cancers14041028</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cancers14041028</ArticleId><ArticleId IdType="pubmed">35205776</ArticleId></ArticleIdList></Reference><Reference><Citation>Chamundeeswari M, Jeslin J, Verma ML (2019) Nanocarriers for drug delivery applications. Environ Chem Lett 17:849–865. https://doi.org/10.1007/s10311-018-00841-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10311-018-00841-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Chawla M, Kaushik RD, Singh J, Manila (2020) Optimization and computational studies evaluating molecular dynamics of EDA cored polymeric dendrimer. Sci Rep 10:21977. https://doi.org/10.1038/s41598-020-77540-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-020-77540-x</ArticleId><ArticleId IdType="pubmed">33319804</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen K, Collins G, Wang H, Toh JWT (2021) Pathological features and prognostication in colorectal cancer. Curr Oncol 28:5356–5383. https://doi.org/10.3390/curroncol28060447</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/curroncol28060447</ArticleId><ArticleId IdType="pubmed">34940086</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen L, Yang F, Chen S, Tai J (2022) Mechanisms on chemotherapy resistance of colorectal cancer stem cells and research progress of reverse transformation: a mini-review. Front Med 9. https://doi.org/10.3389/fmed.2022.995882</Citation></Reference><Reference><Citation>Cheng R, Liu L, Xiang Y et al (2020) Advanced liposome-loaded scaffolds for therapeutic and tissue engineering applications. Biomaterials 232:119706. https://doi.org/10.1016/j.biomaterials.2019.119706</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biomaterials.2019.119706</ArticleId><ArticleId IdType="pubmed">31918220</ArticleId></ArticleIdList></Reference><Reference><Citation>Chis AA, Dobrea C, Morgovan C et al (2020) Applications and limitations of dendrimers in biomedicine. Molecules 25:3982. https://doi.org/10.3390/molecules25173982</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/molecules25173982</ArticleId><ArticleId IdType="pubmed">32882920</ArticleId><ArticleId IdType="pmc">7504821</ArticleId></ArticleIdList></Reference><Reference><Citation>Corrie L, Gulati M, Kapoor B et al (2023) Polysaccharide-based nano-delivery systems for the treatment of colorectal cancer. In: Sobti RC, Ganguly NK, Kumar R (eds) Handbook of Oncobiology: From Basic to Clinical Sciences. Springer Nature, Singapore, pp 1–26</Citation></Reference><Reference><Citation>Coughlin SS (2020) Social determinants of colorectal cancer risk, stage, and survival: a systematic review. Int J Colorectal Dis 35:985–995. https://doi.org/10.1007/s00384-020-03585-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00384-020-03585-z</ArticleId><ArticleId IdType="pubmed">32314192</ArticleId></ArticleIdList></Reference><Reference><Citation>De Leo V, Milano F, Agostiano A, Catucci L (2021) Recent advancements in polymer/liposome assembly for drug delivery: from surface modifications to hybrid vesicles. Polymers 13:1027. https://doi.org/10.3390/polym13071027</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/polym13071027</ArticleId><ArticleId IdType="pubmed">33810273</ArticleId><ArticleId IdType="pmc">8037206</ArticleId></ArticleIdList></Reference><Reference><Citation>de Martel C, Georges D, Bray F et al (2020) Global burden of cancer attributable to infections in 2018: a worldwide incidence analysis. Lancet Glob Health 8:e180–e190. https://doi.org/10.1016/S2214-109X(19)30488-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2214-109X(19)30488-7</ArticleId><ArticleId IdType="pubmed">31862245</ArticleId></ArticleIdList></Reference><Reference><Citation>Ding J, Chen J, Gao L et al (2019) Engineered nanomedicines with enhanced tumor penetration. Nano Today 29:100800. https://doi.org/10.1016/j.nantod.2019.100800</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nantod.2019.100800</ArticleId></ArticleIdList></Reference><Reference><Citation>Dobrzynska M, Napierala M, Florek E (2020) Flavonoid nanoparticles: a promising approach for cancer therapy. Biomolecules 10:1268. https://doi.org/10.3390/biom10091268</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biom10091268</ArticleId><ArticleId IdType="pubmed">32887473</ArticleId><ArticleId IdType="pmc">7564267</ArticleId></ArticleIdList></Reference><Reference><Citation>Edis Z, Wang J, Waqas MK et al (2021) Nanocarriers-mediated drug delivery systems for anticancer agents: an overview and perspectives. Int J Nanomedicine 16:1313–1330. https://doi.org/10.2147/IJN.S289443</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/IJN.S289443</ArticleId><ArticleId IdType="pubmed">33628022</ArticleId><ArticleId IdType="pmc">7898224</ArticleId></ArticleIdList></Reference><Reference><Citation>Flatin BTB, Vedeld HM, Pinto R et al (2021) Multiregional assessment of CIMP in primary colorectal cancers: phenotype concordance but marker variability. Int J Cancer 148:1652–1657. https://doi.org/10.1002/ijc.33425</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ijc.33425</ArticleId><ArticleId IdType="pubmed">33284993</ArticleId></ArticleIdList></Reference><Reference><Citation>Franco MS, Oliveira MC (2019) Liposomes co- encapsulating anticancer drugs in synergistic ratios as an approach to promote increased efficacy and greater safety. Anticancer Agents Med Chem 19:17–28. https://doi.org/10.2174/1871520618666180420170124</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1871520618666180420170124</ArticleId><ArticleId IdType="pubmed">29692263</ArticleId></ArticleIdList></Reference><Reference><Citation>Gajjar S, Patel BM (2021) Common targets for a deadly duo of diabetes mellitus and colon cancer: catching two fish with one worm. Eur J Pharmacol 893:173805. https://doi.org/10.1016/j.ejphar.2020.173805</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejphar.2020.173805</ArticleId><ArticleId IdType="pubmed">33359221</ArticleId></ArticleIdList></Reference><Reference><Citation>Gangi A, Lu SC (2020) Chemotherapy-associated liver injury in colorectal cancer. Ther Adv Gastroenterol 13:1756284820924194. https://doi.org/10.1177/1756284820924194</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1756284820924194</ArticleId></ArticleIdList></Reference><Reference><Citation>Ge P, Niu B, Wu Y et al (2020) Enhanced cancer therapy of celastrol in vitro and in vivo by smart dendrimers delivery with specificity and biosafety. Chem Eng J 383:123228. https://doi.org/10.1016/j.cej.2019.123228</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cej.2019.123228</ArticleId></ArticleIdList></Reference><Reference><Citation>Gelibter AJ, Caponnetto S, Urbano F et al (2019) Adjuvant chemotherapy in resected colon cancer: when, how and how long? Surg Oncol 30:100–107. https://doi.org/10.1016/j.suronc.2019.06.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.suronc.2019.06.003</ArticleId><ArticleId IdType="pubmed">31500770</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghanbari-Movahed M, Kaceli T, Mondal A et al (2021) Recent advances in improved anticancer efficacies of camptothecin nano-formulations: a systematic review. Biomedicines 9:480. https://doi.org/10.3390/biomedicines9050480</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biomedicines9050480</ArticleId><ArticleId IdType="pubmed">33925750</ArticleId><ArticleId IdType="pmc">8146681</ArticleId></ArticleIdList></Reference><Reference><Citation>Gowd V, Ahmad A, Tarique M et al (2022) Advancement of cancer immunotherapy using nanoparticles-based nanomedicine. Semin Cancer Biol 86:624–644. https://doi.org/10.1016/j.semcancer.2022.03.026</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.semcancer.2022.03.026</ArticleId><ArticleId IdType="pubmed">35378274</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo Y, Wang M, Zou Y et al (2022) Mechanisms of chemotherapeutic resistance and the application of targeted nanoparticles for enhanced chemotherapy in colorectal cancer. J Nanobiotechnology 20:371. https://doi.org/10.1186/s12951-022-01586-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12951-022-01586-4</ArticleId><ArticleId IdType="pubmed">35953863</ArticleId><ArticleId IdType="pmc">9367166</ArticleId></ArticleIdList></Reference><Reference><Citation>Gyanani V, Haley JC, Goswami R (2021) Challenges of current anticancer treatment approaches with focus on liposomal drug delivery systems. Pharmaceuticals 14:835. https://doi.org/10.3390/ph14090835</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ph14090835</ArticleId><ArticleId IdType="pubmed">34577537</ArticleId><ArticleId IdType="pmc">8466509</ArticleId></ArticleIdList></Reference><Reference><Citation>Haider M, Zaki KZ, El Hamshary MR et al (2022) Polymeric nanocarriers: a promising tool for early diagnosis and efficient treatment of colorectal cancer. J Adv Res 39:237–255. https://doi.org/10.1016/j.jare.2021.11.008</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jare.2021.11.008</ArticleId><ArticleId IdType="pubmed">35777911</ArticleId></ArticleIdList></Reference><Reference><Citation>Hani U, Honnavalli YK, Begum MY et al (2021) Colorectal cancer: a comprehensive review based on the novel drug delivery systems approach and its management. J Drug Deliv Sci Technol 63:102532. https://doi.org/10.1016/j.jddst.2021.102532</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jddst.2021.102532</ArticleId></ArticleIdList></Reference><Reference><Citation>He Y-C, Hao Z-N, Li Z, Gao D-W (2023) Nanomedicine-based multimodal therapies: recent progress and perspectives in colon cancer. World J Gastroenterol 29:670–681. https://doi.org/10.3748/wjg.v29.i4.670</Citation><ArticleIdList><ArticleId IdType="doi">10.3748/wjg.v29.i4.670</ArticleId><ArticleId IdType="pubmed">36742173</ArticleId><ArticleId IdType="pmc">9896619</ArticleId></ArticleIdList></Reference><Reference><Citation>Hossain MS, Karuniawati H, Jairoun AA et al (2022) Colorectal cancer: a review of carcinogenesis, global epidemiology, current challenges, risk factors, preventive and treatment strategies. Cancers 14:1732. https://doi.org/10.3390/cancers14071732</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cancers14071732</ArticleId><ArticleId IdType="pubmed">35406504</ArticleId><ArticleId IdType="pmc">8996939</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang C, Zhou Y, Feng X et al (2023) Delivery of engineered primary tumor-derived exosomes effectively suppressed the colorectal cancer chemoresistance and liver metastasis. ACS Nano 17:10313–10326. https://doi.org/10.1021/acsnano.3c00668</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acsnano.3c00668</ArticleId><ArticleId IdType="pubmed">37141393</ArticleId></ArticleIdList></Reference><Reference><Citation>Huda S, Alam MA, Sharma PK (2020) Smart nanocarriers-based drug delivery for cancer therapy: an innovative and developing strategy. J Drug Deliv Sci Technol 60:102018. https://doi.org/10.1016/j.jddst.2020.102018</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jddst.2020.102018</ArticleId></ArticleIdList></Reference><Reference><Citation>J V, F S, M M et al (2020) Encapsulation of imatinib in targeted KIT-5 nanoparticles for reducing its cardiotoxicity and hepatotoxicity. Anticancer Agents Med Chem 20. https://doi.org/10.2174/1871520620666200619174323</Citation></Reference><Reference><Citation>Johdi NA, Sukor NF (2020) Colorectal cancer immunotherapy: options and strategies. Front Immunol 11. https://doi.org/10.3389/fimmu.2020.01624</Citation></Reference><Reference><Citation>Kanth P, Inadomi JM (2021) Screening and prevention of colorectal cancer. BMJ 374:n1855. https://doi.org/10.1136/bmj.n1855</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.n1855</ArticleId><ArticleId IdType="pubmed">34526356</ArticleId></ArticleIdList></Reference><Reference><Citation>Karpisheh V, Nikkhoo A, Hojjat-Farsangi M et al (2019) Prostaglandin E2 as a potent therapeutic target for treatment of colon cancer. Prostaglandins Other Lipid Mediat 144:106338. https://doi.org/10.1016/j.prostaglandins.2019.106338</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.prostaglandins.2019.106338</ArticleId><ArticleId IdType="pubmed">31100474</ArticleId></ArticleIdList></Reference><Reference><Citation>Kashyap D, Tuli HS, Yerer MB et al (2021) Natural product-based nanoformulations for cancer therapy: opportunities and challenges. Semin Cancer Biol 69:5–23. https://doi.org/10.1016/j.semcancer.2019.08.014</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.semcancer.2019.08.014</ArticleId><ArticleId IdType="pubmed">31421264</ArticleId></ArticleIdList></Reference><Reference><Citation>Kasi PB, Mallela VR, Ambrozkiewicz F et al (2023) Theranostics nanomedicine applications for colorectal cancer and metastasis: recent advances. Int J Mol Sci 24:7922. https://doi.org/10.3390/ijms24097922</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms24097922</ArticleId><ArticleId IdType="pubmed">37175627</ArticleId><ArticleId IdType="pmc">10178331</ArticleId></ArticleIdList></Reference><Reference><Citation>Kesharwani P, Choudhury H, Meher JG et al (2019) Dendrimer-entrapped gold nanoparticles as promising nanocarriers for anticancer therapeutics and imaging. Prog Mater Sci 103:484–508. https://doi.org/10.1016/j.pmatsci.2019.03.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pmatsci.2019.03.003</ArticleId></ArticleIdList></Reference><Reference><Citation>Khan FA, Albalawi R, Pottoo FH (2022) Trends in targeted delivery of nanomaterials in colon cancer diagnosis and treatment. Med Res Rev 42:227–258. https://doi.org/10.1002/med.21809</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/med.21809</ArticleId><ArticleId IdType="pubmed">33891325</ArticleId></ArticleIdList></Reference><Reference><Citation>Khuntawee W, Amornloetwattana R, Vongsangnak W et al (2021) In silico and in vitro design of cordycepin encapsulation in liposomes for colon cancer treatment. RSC Adv 11:8475–8484. https://doi.org/10.1039/D1RA00038A</Citation><ArticleIdList><ArticleId IdType="doi">10.1039/D1RA00038A</ArticleId><ArticleId IdType="pubmed">35423402</ArticleId><ArticleId IdType="pmc">8695206</ArticleId></ArticleIdList></Reference><Reference><Citation>Kotani D, Oki E, Nakamura Y et al (2023) Molecular residual disease and efficacy of adjuvant chemotherapy in patients with colorectal cancer. Nat Med 29:127–134. https://doi.org/10.1038/s41591-022-02115-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-022-02115-4</ArticleId><ArticleId IdType="pubmed">36646802</ArticleId><ArticleId IdType="pmc">9873552</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumari Singh S, Solanki R, Patel S (2024) Nano pharmaceutical delivery in combating colorectal cancer. Med Drug Discov 21:100173. https://doi.org/10.1016/j.medidd.2023.100173</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.medidd.2023.100173</ArticleId></ArticleIdList></Reference><Reference><Citation>Lan J, Sun L, Xu F et al (2019) M2 macrophage-derived exosomes promote cell migration and invasion in colon cancer. Cancer Res 79:146–158. https://doi.org/10.1158/0008-5472.CAN-18-0014</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/0008-5472.CAN-18-0014</ArticleId><ArticleId IdType="pubmed">30401711</ArticleId></ArticleIdList></Reference><Reference><Citation>Langridge TD, Gemeinhart RA (2020) Toward understanding polymer micelle stability: density ultracentrifugation offers insight into polymer micelle stability in human fluids. J Control Release off J Control Release Soc 319:157–167. https://doi.org/10.1016/j.jconrel.2019.12.038</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jconrel.2019.12.038</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee CS, Song IH, Lee A et al (2021) Enhancing the landscape of colorectal cancer using targeted deep sequencing. Sci Rep 11:8154. https://doi.org/10.1038/s41598-021-87486-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-021-87486-3</ArticleId><ArticleId IdType="pubmed">33854094</ArticleId><ArticleId IdType="pmc">8046812</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewandowska A, Rudzki G, Lewandowski T et al (2022) Risk factors for the diagnosis of colorectal cancer. Cancer Control 29:10732748211056692. https://doi.org/10.1177/10732748211056692</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/10732748211056692</ArticleId><ArticleId IdType="pubmed">35000418</ArticleId><ArticleId IdType="pmc">8753079</ArticleId></ArticleIdList></Reference><Reference><Citation>Li J, Ma X, Chakravarti D et al (2021) Genetic and biological hallmarks of colorectal cancer. Genes Dev 35:787–820. https://doi.org/10.1101/gad.348226.120</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/gad.348226.120</ArticleId><ArticleId IdType="pubmed">34074695</ArticleId><ArticleId IdType="pmc">8168558</ArticleId></ArticleIdList></Reference><Reference><Citation>Liebl MC, Hofmann TG (2021) The role of p53 signaling in colorectal cancer. Cancers 13:2125. https://doi.org/10.3390/cancers13092125</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cancers13092125</ArticleId><ArticleId IdType="pubmed">33924934</ArticleId><ArticleId IdType="pmc">8125348</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma Y-S, Li W, Liu Y et al (2020) Targeting colorectal cancer stem cells as an effective treatment for colorectal cancer. Technol Cancer Res Treat 19:1533033819892261. https://doi.org/10.1177/1533033819892261</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1533033819892261</ArticleId><ArticleId IdType="pubmed">32748700</ArticleId><ArticleId IdType="pmc">7785997</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma S, Zhang J, Yan T et al (2023) Novel strategies to reverse chemoresistance in colorectal cancer. Cancer Med 12:11073–11096. https://doi.org/10.1002/cam4.5594</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cam4.5594</ArticleId><ArticleId IdType="pubmed">36645225</ArticleId><ArticleId IdType="pmc">10242875</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehta A, Patel BM (2019) Therapeutic opportunities in colon cancer: focus on phosphodiesterase inhibitors. Life Sci 230:150–161. https://doi.org/10.1016/j.lfs.2019.05.043</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lfs.2019.05.043</ArticleId><ArticleId IdType="pubmed">31125564</ArticleId></ArticleIdList></Reference><Reference><Citation>Mianowska M, Zaremba-Czogalla M, Zygmunt A et al (2024) Dual role of vitamin C-encapsulated liposomal berberine in effective colon anticancer immunotherapy. Pharmaceuticals 17:5. https://doi.org/10.3390/ph17010005</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ph17010005</ArticleId></ArticleIdList></Reference><Reference><Citation>Mittal P, Saharan A, Verma R et al (2021) Dendrimers: a new race of pharmaceutical nanocarriers. BioMed Res Int 2021:8844030. https://doi.org/10.1155/2021/8844030</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2021/8844030</ArticleId><ArticleId IdType="pubmed">33644232</ArticleId><ArticleId IdType="pmc">7902124</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris VK, Kennedy EB, Baxter NN et al (2023) Treatment of metastatic colorectal cancer: ASCO guideline. J Clin Oncol 41:678–700. https://doi.org/10.1200/JCO.22.01690</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.22.01690</ArticleId><ArticleId IdType="pubmed">36252154</ArticleId></ArticleIdList></Reference><Reference><Citation>Naeimi R, Najafi R, Molaei P et al (2022) Nanoparticles: the future of effective diagnosis and treatment of colorectal cancer? Eur J Pharmacol 936:175350. https://doi.org/10.1016/j.ejphar.2022.175350</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejphar.2022.175350</ArticleId><ArticleId IdType="pubmed">36306928</ArticleId></ArticleIdList></Reference><Reference><Citation>Navya PN, Kaphle A, Srinivas SP et al (2019) Current trends and challenges in cancer management and therapy using designer nanomaterials. Nano Converg 6:23. https://doi.org/10.1186/s40580-019-0193-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40580-019-0193-2</ArticleId><ArticleId IdType="pubmed">31304563</ArticleId><ArticleId IdType="pmc">6626766</ArticleId></ArticleIdList></Reference><Reference><Citation>Ogunwobi OO, Mahmood F, Akingboye A (2020) Biomarkers in colorectal cancer: current research and future prospects. Int J Mol Sci 21:5311. https://doi.org/10.3390/ijms21155311</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms21155311</ArticleId><ArticleId IdType="pubmed">32726923</ArticleId><ArticleId IdType="pmc">7432436</ArticleId></ArticleIdList></Reference><Reference><Citation>Padhi S, Behera A, Hasnain MS, Nayak AK (2022) Chapter 5 - chitosan in colon-targeted drug delivery. In: Hasnain MS, Beg S, Nayak AK (eds) Chitosan in Drug Delivery. Academic Press, pp 107–132</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/B978-0-12-819336-5.00019-4</ArticleId></ArticleIdList></Reference><Reference><Citation>Pahwa R, Bajaj R, Bhateja P, Piplani M (2021) Recent advances in colon drug delivery technology. Drug Deliv Lett 11:110–135. https://doi.org/10.2174/2210303111666210129143612</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/2210303111666210129143612</ArticleId></ArticleIdList></Reference><Reference><Citation>Parhi R (2020) Drug delivery applications of chitin and chitosan: a review. Environ Chem Lett 18:577–594. https://doi.org/10.1007/s10311-020-00963-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10311-020-00963-5</ArticleId></ArticleIdList></Reference><Reference><Citation>Pathak PS, Chan G, Deming DA, Chee CE (2024) State-of-the-art management of colorectal cancer: treatment advances and innovation. Am Soc Clin Oncol Educ Book 44:e438466. https://doi.org/10.1200/EDBK_438466</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/EDBK_438466</ArticleId><ArticleId IdType="pubmed">38768405</ArticleId></ArticleIdList></Reference><Reference><Citation>Patil TS, Deshpande AS (2020) Mannosylated nanocarriers mediated site-specific drug delivery for the treatment of cancer and other infectious diseases: a state of the art review. J Control Release Off J Control Release Soc 320:239–252. https://doi.org/10.1016/j.jconrel.2020.01.046</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jconrel.2020.01.046</ArticleId></ArticleIdList></Reference><Reference><Citation>Peer D, Karp J, Hong S et al (2020) Nanocarriers as an emerging platform for cancer therapy. Nano-Enabled Med Appl. https://doi.org/10.1201/9780429399039-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1201/9780429399039-2</ArticleId></ArticleIdList></Reference><Reference><Citation>Perumal S, Atchudan R, Lee W (2022) A review of polymeric micelles and their applications. Polymers 14:2510. https://doi.org/10.3390/polym14122510</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/polym14122510</ArticleId><ArticleId IdType="pubmed">35746086</ArticleId></ArticleIdList></Reference><Reference><Citation>Pishavar E, Ramezani M, Hashemi M (2019) Co-delivery of doxorubicin and TRAIL plasmid by modified PAMAM dendrimer in colon cancer cells, in vitro and in vivo evaluation. Drug Dev Ind Pharm 45:1931–1939. https://doi.org/10.1080/03639045.2019.1680995</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/03639045.2019.1680995</ArticleId><ArticleId IdType="pubmed">31609130</ArticleId></ArticleIdList></Reference><Reference><Citation>Rajendran S, Ravi SN, Nair VM et al (2024) Recent development and future aspects: nano-based drug delivery system in cancer therapy. Top Catal 67:203–217. https://doi.org/10.1007/s11244-023-01893-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11244-023-01893-6</ArticleId></ArticleIdList></Reference><Reference><Citation>Raskov H, Søby JH, Troelsen J et al (2020) Driver gene mutations and epigenetics in colorectal cancer. Ann Surg 271:75. https://doi.org/10.1097/SLA.0000000000003393</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/SLA.0000000000003393</ArticleId><ArticleId IdType="pubmed">31188207</ArticleId></ArticleIdList></Reference><Reference><Citation>Ren R, Sun H, Ma C et al (2019) Colon cancer cells secrete exosomes to promote self-proliferation by shortening mitosis duration and activation of STAT3 in a hypoxic environment. Cell Biosci 9:62. https://doi.org/10.1186/s13578-019-0325-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13578-019-0325-8</ArticleId><ArticleId IdType="pubmed">31402975</ArticleId></ArticleIdList></Reference><Reference><Citation>Rm E, M JI, G A et al (2020) Synthesis and characterization of dendrimer-based polysarcosine star polymers: well-defined, versatile platforms designed for drug-delivery applications. Biomacromolecules 21. https://doi.org/10.1021/acs.biomac.0c00768</Citation></Reference><Reference><Citation>Roeder F, Meldolesi E, Gerum S et al (2020) Recent advances in (chemo-)radiation therapy for rectal cancer: a comprehensive review. Radiat Oncol 15:262. https://doi.org/10.1186/s13014-020-01695-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13014-020-01695-0</ArticleId><ArticleId IdType="pubmed">33172475</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryzhov A, Bray F, Ferlay J et al (2020) Recent cancer incidence trends in Ukraine and short-term predictions to 2022. Cancer Epidemiol 65:101663. https://doi.org/10.1016/j.canep.2019.101663</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.canep.2019.101663</ArticleId><ArticleId IdType="pubmed">31882366</ArticleId></ArticleIdList></Reference><Reference><Citation>Sang R, Stratton B, Engel A, Deng W (2021) Liposome technologies towards colorectal cancer therapeutics. Acta Biomater 127:24–40. https://doi.org/10.1016/j.actbio.2021.03.055</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.actbio.2021.03.055</ArticleId><ArticleId IdType="pubmed">33812076</ArticleId></ArticleIdList></Reference><Reference><Citation>Sawicki T, Ruszkowska M, Danielewicz A et al (2021) A review of colorectal cancer in terms of epidemiology, risk factors, development, symptoms and diagnosis. Cancers 13:2025. https://doi.org/10.3390/cancers13092025</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cancers13092025</ArticleId><ArticleId IdType="pubmed">33922197</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmitt M, Greten FR (2021) The inflammatory pathogenesis of colorectal cancer. Nat Rev Immunol 21:653–667. https://doi.org/10.1038/s41577-021-00534-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41577-021-00534-x</ArticleId><ArticleId IdType="pubmed">33911231</ArticleId></ArticleIdList></Reference><Reference><Citation>Selvam C, Prabu SL, Jordan BC et al (2019) Molecular mechanisms of curcumin and its analogs in colon cancer prevention and treatment. Life Sci 239:117032. https://doi.org/10.1016/j.lfs.2019.117032</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lfs.2019.117032</ArticleId><ArticleId IdType="pubmed">31704450</ArticleId></ArticleIdList></Reference><Reference><Citation>Senthil Kumar C, Thangam R, Mary SA et al (2020) Targeted delivery and apoptosis induction of trans-resveratrol-ferulic acid loaded chitosan coated folic acid conjugate solid lipid nanoparticles in colon cancer cells. Carbohydr Polym 231:115682. https://doi.org/10.1016/j.carbpol.2019.115682</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.carbpol.2019.115682</ArticleId><ArticleId IdType="pubmed">31888816</ArticleId></ArticleIdList></Reference><Reference><Citation>Shah A, Aftab S, Nisar J et al (2021) Nanocarriers for targeted drug delivery. J Drug Deliv Sci Technol 62:102426. https://doi.org/10.1016/j.jddst.2021.102426</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jddst.2021.102426</ArticleId></ArticleIdList></Reference><Reference><Citation>Shin AE, Giancotti FG, Rustgi AK (2023) Metastatic colorectal cancer: mechanisms and emerging therapeutics. Trends Pharmacol Sci 44:222–236. https://doi.org/10.1016/j.tips.2023.01.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tips.2023.01.003</ArticleId><ArticleId IdType="pubmed">36828759</ArticleId></ArticleIdList></Reference><Reference><Citation>Siegel RL, Miller KD, Goding Sauer A et al (2020) Colorectal cancer statistics, 2020. CA Cancer J Clin 70:145–164. https://doi.org/10.3322/caac.21601</Citation><ArticleIdList><ArticleId IdType="doi">10.3322/caac.21601</ArticleId><ArticleId IdType="pubmed">32133645</ArticleId></ArticleIdList></Reference><Reference><Citation>Ștefan G, Hosu O, De Wael K et al (2021) Aptamers in biomedicine: selection strategies and recent advances. Electrochim Acta 376:137994. https://doi.org/10.1016/j.electacta.2021.137994</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.electacta.2021.137994</ArticleId></ArticleIdList></Reference><Reference><Citation>Tapial S, Olmedillas-López S, Rueda D et al (2019) CIMP-positive status is more representative in multiple colorectal cancers than in unique primary colorectal cancers. Sci Rep 9:10516. https://doi.org/10.1038/s41598-019-47014-w</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-019-47014-w</ArticleId><ArticleId IdType="pubmed">31324877</ArticleId></ArticleIdList></Reference><Reference><Citation>Tiwari C, Tomer J, Kumar D (2024) Liposomal drug delivery: progress, clinical outlook, and ongoing challenges. Recent Adv Drug Deliv Formul Former Recent Pat Drug Deliv Formul 18:157–169. https://doi.org/10.2174/0126673878300031240703070511</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/0126673878300031240703070511</ArticleId></ArticleIdList></Reference><Reference><Citation>Tolba MF (2020) Revolutionizing the landscape of colorectal cancer treatment: the potential role of immune checkpoint inhibitors. Int J Cancer 147:2996–3006. https://doi.org/10.1002/ijc.33056</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ijc.33056</ArticleId><ArticleId IdType="pubmed">32415713</ArticleId></ArticleIdList></Reference><Reference><Citation>Umwali Y, Yue C-B, Gabriel ANA et al (2021) Roles of exosomes in diagnosis and treatment of colorectal cancer. World J Clin Cases 9:4467–4479. https://doi.org/10.12998/wjcc.v9.i18.4467</Citation><ArticleIdList><ArticleId IdType="doi">10.12998/wjcc.v9.i18.4467</ArticleId><ArticleId IdType="pubmed">34222415</ArticleId></ArticleIdList></Reference><Reference><Citation>Vakhshiteh F, Hassani S, Momenifar N, Pakdaman F (2021) Exosomal circRNAs: new players in colorectal cancer. Cancer Cell Int 21:483. https://doi.org/10.1186/s12935-021-02112-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12935-021-02112-6</ArticleId><ArticleId IdType="pubmed">34521402</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Valk MJM, Marijnen CAM, van Etten B et al (2020) Compliance and tolerability of short-course radiotherapy followed by preoperative chemotherapy and surgery for high-risk rectal cancer – results of the international randomized RAPIDO-trial. Radiother Oncol 147:75–83. https://doi.org/10.1016/j.radonc.2020.03.011</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.radonc.2020.03.011</ArticleId><ArticleId IdType="pubmed">32240909</ArticleId></ArticleIdList></Reference><Reference><Citation>Vega-Vásquez P, Mosier NS, Irudayaraj J (2020) Nanoscale drug delivery systems: from medicine to agriculture. Front Bioeng Biotechnol 8. https://doi.org/10.3389/fbioe.2020.00079</Citation></Reference><Reference><Citation>Vinchhi P, Patel MM (2021) Triumph against cancer: invading colorectal cancer with nanotechnology. Expert Opin Drug Deliv 18:1169–1192. https://doi.org/10.1080/17425247.2021.1889512</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/17425247.2021.1889512</ArticleId><ArticleId IdType="pubmed">33567909</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang M, Su Z, Amoah Barnie P (2020) Crosstalk among colon cancer-derived exosomes, fibroblast-derived exosomes, and macrophage phenotypes in colon cancer metastasis. Int Immunopharmacol 81:106298. https://doi.org/10.1016/j.intimp.2020.106298</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.intimp.2020.106298</ArticleId><ArticleId IdType="pubmed">32058925</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Q, Shen X, Chen G, Du J (2022) Drug resistance in colorectal cancer: from mechanism to clinic. Cancers 14:2928. https://doi.org/10.3390/cancers14122928</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cancers14122928</ArticleId><ArticleId IdType="pubmed">35740594</ArticleId><ArticleId IdType="pmc">9221177</ArticleId></ArticleIdList></Reference><Reference><Citation>Xi Y, Xu P (2021) Global colorectal cancer burden in 2020 and projections to 2040. Transl Oncol 14:101174. https://doi.org/10.1016/j.tranon.2021.101174</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tranon.2021.101174</ArticleId><ArticleId IdType="pubmed">34243011</ArticleId><ArticleId IdType="pmc">8273208</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiao Y, Zhong J, Zhong B et al (2020) Exosomes as potential sources of biomarkers in colorectal cancer. Cancer Lett 476:13–22. https://doi.org/10.1016/j.canlet.2020.01.033</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.canlet.2020.01.033</ArticleId><ArticleId IdType="pubmed">32044357</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie Y-H, Chen Y-X, Fang J-Y (2020) Comprehensive review of targeted therapy for colorectal cancer. Signal Transduct Target Ther 5:1–30. https://doi.org/10.1038/s41392-020-0116-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41392-020-0116-z</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamamoto T, Kawada K, Obama K (2021) Inflammation-related biomarkers for the prediction of prognosis in colorectal cancer patients. Int J Mol Sci 22:8002. https://doi.org/10.3390/ijms22158002</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms22158002</ArticleId><ArticleId IdType="pubmed">34360768</ArticleId><ArticleId IdType="pmc">8348168</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan W, Leung SS, To KK (2020) Updates on the use of liposomes for active tumor targeting in cancer therapy. Nanomed 15:303–318. https://doi.org/10.2217/nnm-2019-0308</Citation><ArticleIdList><ArticleId IdType="doi">10.2217/nnm-2019-0308</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang J, Tao R, Wang L et al (2019) Thermosensitive micelles encapsulating phenylalanine ammonia lyase act as a sustained and efficacious therapy against colorectal cancer. J Biomed Nanotechnol 15:717–727. https://doi.org/10.1166/jbn.2019.2734</Citation><ArticleIdList><ArticleId IdType="doi">10.1166/jbn.2019.2734</ArticleId><ArticleId IdType="pubmed">30841965</ArticleId></ArticleIdList></Reference><Reference><Citation>Yousefi M, Narmani A, Jafari SM (2020) Dendrimers as efficient nanocarriers for the protection and delivery of bioactive phytochemicals. Adv Colloid Interface Sci 278:102125. https://doi.org/10.1016/j.cis.2020.102125</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cis.2020.102125</ArticleId><ArticleId IdType="pubmed">32109595</ArticleId></ArticleIdList></Reference><Reference><Citation>Yue Z, Zhu Y, Chen T et al (2024) Bletilla striata polysaccharide-coated andrographolide nanomicelles for targeted drug delivery to enhance anti-colon cancer efficacy. Front Immunol 15. https://doi.org/10.3389/fimmu.2024.1380229</Citation></Reference><Reference><Citation>Zhang X, Song H, Canup BSB, Xiao B (2020) Orally delivered targeted nanotherapeutics for the treatment of colorectal cancer. Expert Opin Drug Deliv 17:781–790. https://doi.org/10.1080/17425247.2020.1748005</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/17425247.2020.1748005</ArticleId><ArticleId IdType="pubmed">32237921</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang M-M, Wang D, Lu F et al (2021) Identification of the active substances and mechanisms of ginger for the treatment of colon cancer based on network pharmacology and molecular docking. BioData Min 14:1. https://doi.org/10.1186/s13040-020-00232-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13040-020-00232-9</ArticleId><ArticleId IdType="pubmed">33430939</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang S, Zhang H, Song P et al (2023) Colorectal cancer therapy mediated by nanomedicines. Chem Commun 59:4423–4435. https://doi.org/10.1039/D2CC06212G</Citation><ArticleIdList><ArticleId IdType="doi">10.1039/D2CC06212G</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao P, Yin W, Wu A et al (2020) Dual-targeting to cancer cells and M2 macrophages via biomimetic delivery of mannosylated albumin nanoparticles for drug-resistant cancer therapy. Adv Funct Mater 30:1910144. https://doi.org/10.1002/adfm.201910144</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/adfm.201910144</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao H, Ming T, Tang S et al (2022) Wnt signaling in colorectal cancer: pathogenic role and therapeutic target. Mol Cancer 21:144. https://doi.org/10.1186/s12943-022-01616-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12943-022-01616-7</ArticleId><ArticleId IdType="pubmed">35836256</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu G, Pei L, Xia H et al (2021) Role of oncogenic KRAS in the prognosis, diagnosis and treatment of colorectal cancer. Mol Cancer 20:143. https://doi.org/10.1186/s12943-021-01441-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12943-021-01441-4</ArticleId><ArticleId IdType="pubmed">34742312</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>